Quizartinib inhibits necroptosis by targeting receptor‐interacting serine/threonine protein kinase 1

Abstract

Systemic inflammatory response syndrome (SIRS), at least in part driven by necroptosis, is characterized by life‐threatening multiple organ failure. Blocking the progression of SIRS and consequent multiple organ dysfunction is challenging. Receptor‐interacting serine/threonine protein kinase 1 (RIPK1) is an important cell death and inflammatory mediator, making it a potential treatment target in several diseases. Here, using a drug repurposing approach, we show that inhibiting RIPK1 is also an effective treatment for SIRS. We performed cell‐based high‐throughput drug screening of an US Food and Drug Administration (FDA)‐approved drug library that contains 1953 drugs to identify effective inhibitors of necroptotic cell death by SYTOX green staining. Dose–response validation of the top candidate, quizartinib, was conducted in two cell lines of HT‐22 and MEFs. The effect of quizartinib on necroptosis‐related proteins was evaluated using western blotting, immunoprecipitation, and an in vitro RIPK1 kinase assay. The in vivo effects of quizartinib were assessed in a murine tumor necrosis factor α (TNFα)‐induced SIRS model. High‐throughput screening identified quizartinib as the top “hit” in the compound library that rescued cells from necroptosis in vitro. Quizartinib inhibited necroptosis by directly inhibiting RIPK1 kinase activity and blocking downstream complex IIb formation. Furthermore, quizartinib protected mice against TNFα‐induced SIRS. Quizartinib, as an FDA‐approved drug with proven safety and efficacy, was repurposed for targeted inhibition of RIPK1. This work provides essential preclinical data for transferring quizartinib to the treatment of RIPK1‐dependent necroptosis‐induced inflammatory diseases, including SIRS.